PF-08634404

**PF-08634404** is a bispecific monoclonal antibody that simultaneously targets **PD-1** and **VEGF**, licensed by Pfizer from 3SBio for $1.25 billion. It blocks PD-1 to enhance T-cell anti-tumor activity while inhibiting VEGF to suppress tumor angiogenesis, aiming to improve efficacy over PD-1 monotherapies like Keytruda or anti-VEGF agents like bevacizumab. Primarily developed for advanced solid tumors, it shows promising phase 2 data in NSCLC (ORR 58.6-69.2% with chemo) and SCLC, with ongoing phase 3 trials versus standards of care in NSCLC and colorectal cancer, plus phase 1/2 in liver, urothelial, renal cancers, and ADC combinations.[1][2][10]

Other names

PD-1/VEGF bispecific